

Accepted Manuscript

Complementary and Alternative Medicines Used by Patients With Inflammatory Bowel Diseases

Adam S. Cheifetz, MD, Robert Gianotti, MD, Raphael Lubert, MD, Peter R. Gibson, MD

PII: S0016-5085(16)35193-9
DOI: [10.1053/j.gastro.2016.10.004](https://doi.org/10.1053/j.gastro.2016.10.004)
Reference: YGAST 60762

To appear in: *Gastroenterology*
Accepted Date: 6 October 2016

Please cite this article as: Cheifetz AS, Gianotti R, Lubert R, Gibson PR, Complementary and Alternative Medicines Used by Patients With Inflammatory Bowel Diseases, *Gastroenterology* (2016), doi: 10.1053/j.gastro.2016.10.004.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Gastro 16-01543

Complementary and Alternative Medicines Used by Patients With Inflammatory Bowel Diseases

Adam S. Cheifetz, MD¹, Robert Gianotti, MD¹, Raphael Luber, MD², Peter R. Gibson, MD²

¹ Department of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, MA

² Department of Gastroenterology, Alfred Hospital and Monash University, Melbourne, Australia

Note: All authors have made equivalent/equal contributions

Corresponding author: Professor Peter Gibson

Department of Gastroenterology, Alfred Hospital, 99 Commercial Road, Melbourne, Victoria 3004, Australia. Tel +61 9076 3315; Fax +61 3 9076 2194; email: peter.gibson@monash.edu

Grant Support: none

Abbreviations: CAM, complementary and alternative medicines; CB, cannabinoid; CD, Crohn's disease; CDAI, Crohn's disease activity index; EPA, eicosapentaenoic acid; IBD, inflammatory bowel diseases; IL, interleukin; n-3 PUFAs, omega-3 polyunsaturated fatty acids; THC, delta-9-tetrahydrocannabinol; TNBS, trinitrobenzenesulfonic acid; TNF, tumor necrosis factor; UCDAI, ulcerative colitis disease activity index; UC, ulcerative colitis.

Disclosures:

ASC: none related; consulting for Abbvie, Janssen, Takeda, Pfizer, Samsung; RG: none; RL: none; PRG: consulting for AbbVie, Ferring, Janssen, Merck, Nestle Health Science, Danone, Vital Foods, Allergan and Takeda. His institution has received speaking honoraria from AbbVie, Janssen, Ferring, Takeda, Fresenius Kabi, Mylan and Pfizer. He has received research grants for investigator-driven studies from AbbVie, Janssen, Falk Pharma, Danone and A2 Milk Company. His Department financially benefits from the sales of a digital application and booklets on the low FODMAP diet. He has published an educational/recipe book on diet.

Download English Version:

<https://daneshyari.com/en/article/5658310>

Download Persian Version:

<https://daneshyari.com/article/5658310>

[Daneshyari.com](https://daneshyari.com)